Last reviewed · How we verify
4SC-202
At a glance
| Generic name | 4SC-202 |
|---|---|
| Sponsor | 4SC AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (PHASE1, PHASE2)
- Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (PHASE2)
- Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |